Ovagen

Ovagen (EDL, Glu-Asp-Leu) is a synthetic tripeptide from the Khavinson short-peptide bioregulator family, designed as a tissue-selective modulator of hepatic and gastrointestinal gene expression. Unlike growth-factor peptides or receptor agonists, EDL does not bind a membrane receptor — it works by entering the cell, translocating into the nucleus, and directly modulating transcription at specific DNA sites. The practical payoff for physique-focused users is slower: Ovagen does not produce an acute "feel" like BPC-157, but across a 10–30 day cycle it biases aged hepatocytes and enterocytes toward a more proliferative, less senescent phenotype — useful for anyone running hepatotoxic orals, recovering a beat-up liver, or stacking bioregulators for longevity.

Direct DNA Binding and Transcriptional Modulation#

The defining feature of the Khavinson class is that short peptides of 2–4 residues are small enough to be taken up by the PepT1/PepT2 di-/tripeptide transporters, cross the nuclear envelope, and interact directly with DNA. EDL preferentially binds AT-rich regions of gene promoters, where it is proposed to displace or recruit transcription factors and shift expression of nearby genes.

"Short peptides such as EDL can penetrate into the nucleus and interact with DNA, most frequently in AT-rich sites, modulating the expression of target genes." — Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR, Molecules (2021)

This is the mechanistic basis for why Ovagen is dosed as a pulse cycle (10–30 days, 2–3× per year) rather than continuously — the effect is an epigenetic nudge across cumulative exposure, not a plasma-level-dependent acute action. It is also why dose timing within the day is largely irrelevant; cycle adherence matters, clock time does not.

Senescence-Pathway Downregulation (p16/p21/p53) and SIRT6 Upregulation#

In aged renal cell cultures, EDL produced one of the cleaner anti-senescence signals in the Khavinson literature: suppression of the classical senescence markers p16, p21, and p53, alongside upregulation of SIRT6 — a sirtuin heavily implicated in DNA repair, genomic stability, and metabolic regulation.

"After administration of EDL, cultures of old cells significantly reduced expression of p16, p21, p53 and increased the transcription of SIRT6, while proliferative activity was restored toward levels of young cells." — Khavinson VKh, Tarnovskaia SI, Lin'kova NS et al., Advances in Gerontology (2014)

For the longevity-stack audience, this is the headline finding. p16/p21/p53 downregulation plus SIRT6 upregulation is the same axis that rapamycin, NMN, and senolytics target from different angles — Ovagen is the tissue-specific (hepatic/GI/renal) contribution to that stack rather than a systemic mTOR or NAD+ lever.

Hepatocyte Proliferation and Glycogen Restoration#

The organ-specific rationale for Ovagen comes from murine models of chemically induced cirrhosis, where EDL was shown to extend hepatocyte lifespan, increase the fraction of actively dividing hepatocytes (Ki-67+), and restore intracellular glycogen content.

"In murine models of cirrhosis, EDL extended hepatocyte survival, increased Ki-67+ dividing cells, and improved hepatic glycogen storage, supporting its use as a bioregulator of hepatic regeneration." — Marinov MD, PhD, Core Peptides Editorial Review (2022)

The practical translation: when a 17α-alkylated oral is driving hepatocyte stress, elevated transaminases, and cholestatic pressure, Ovagen provides a proliferative/regenerative signal to the surviving hepatocyte pool. It is a facilitator alongside TUDCA (the actual first-line agent for alkylated-oral cholestasis) and NAC (glutathione replenishment) — not a replacement for either. The glycogen-restoration data is also a quiet selling point for users running aggressive cuts or post-refeed recomp protocols, where hepatic glycogen is chronically depleted.

Redox Shift and Antioxidant Enzyme Upregulation#

The fourth mechanism is a straightforward oxidative-stress effect, documented in aged rat kidneys but mechanistically applicable to any tissue handling chronic oxidative load (liver under orals, GI mucosa under alcohol or NSAID stress, aged tissue generally).

"The action of EDL in aged rats significantly decreased the content of oxidatively modified proteins and malondialdehyde, with increased activities of catalase and glutathione peroxidase in renal tissue." — Zamorskii II, Shchudrova TS, Zeleniuk VG, Linkova NS, Nichik TE, Khavinson VKh, Advances in Gerontology (2019)

Lower malondialdehyde (a lipid-peroxidation end-product) plus higher catalase and GPx activity is the textbook "tissue handling oxidative load better" signature. Stacked on top of NAC and the glutathione axis, this is additive rather than redundant — catalase and GPx handle H₂O₂ decomposition directly, while NAC feeds the upstream glutathione pool.

Why the Effect Is Cumulative, Not Acute#

The plasma half-life of an unprotected 375 Da tripeptide is short — well under 30 minutes — which would look like a dealbreaker for any receptor-agonist peptide. For Ovagen it is not, because the mechanism is intracellular DNA binding followed by persistent transcriptional change. A single daily dose loads enough EDL into PepT1-expressing tissue (gut, liver, kidney) to produce measurable shifts in gene expression, and those transcriptional changes outlast the peptide itself by days. Across a 10–30 day cycle, the cumulative epigenetic signal is what drives the outcome — which is also why running Ovagen continuously is considered wasteful by the bioregulator community and why the canonical protocol is pulsed quarterly rather than chronic.

Common (most users)#

Ovagen is among the cleanest peptides in the research-only catalog. The published Khavinson-group work and two decades of commercial Cytogen distribution have not surfaced dose-limiting toxicity, and most users complete a full 10–30 day pulse without noting anything at all. What does show up:

• Mild GI discomfort with oral Cytogen capsules — most often in subjects dosing fully fasted. Shift administration to ~20–30 min before a light meal rather than on a completely empty stomach.
• Transient local injection-site irritation (SC format) — standard reconstituted-peptide behaviour. Rotate sites across the abdomen, swirl rather than shake during reconstitution, and ensure bacteriostatic water is within its 28-day window.
• Subtle / no acute subjective effect — not a side effect so much as a managed expectation. Ovagen does not produce a palpable "feel" like BPC-157 or TB-500. The effect is cumulative across the cycle; judge the protocol on bloodwork (AST, ALT, GGT) and the 30-day mark, not on day three.

Uncommon (dose-dependent or individual)#

These sit mostly in the "theoretical / reported anecdotally" column — the formal literature does not characterize a dose-response toxicity curve for EDL.

• Mild lethargy or "flat" days in the first week of a cycle — reported anecdotally in bioregulator-stacking communities, typically when Ovagen is layered with Epitalon or Vesugen simultaneously. Dropping to a single bioregulator or spacing them sequentially resolves it.
• Disproportionate dosing on the SC format — the milligram-range SC protocols circulating in Western practice (1–2 mg/day) sit 1,000–2,000× above the Khavinson-institute oral-equivalent dose. There is no documented toxicity at those ranges, but there is also no evidence of additional benefit. The defensible ceiling is 100–200 μg SC daily; subjects exceeding that are off-map.
• Bloodwork drift on heavy oral stacks — Ovagen is a facilitator, not a rescue. Protocols pairing it with superdrol, anadrol, or tbol can still produce rising ALT/AST if TUDCA and cycle length are not managed. Check a CMP at day 30 of any oral + Ovagen stack; if GGT is trending up, the issue is the oral, not the peptide.

Rare but serious#

Nothing in this category has been documented for EDL specifically. The following are mechanism-derived cautions rather than reported events:

• Theoretical proliferative concern in occult hepatic malignancy — EDL stimulates hepatocyte proliferation (Ki-67+ cell fraction increases in cirrhosis models per the Core Peptides review). The mechanism does not appear tumour-selective, so any subject with known or suspected hepatocellular carcinoma, cholangiocarcinoma, or unexplained persistent hepatic lesions should be excluded from the protocol. Unexplained rapid weight loss, jaundice, or RUQ pain during a cycle is grounds to discontinue and image.
• Hypersensitivity / allergic reaction — low-incidence but possible with any peptide. Urticaria, facial swelling, or respiratory symptoms after a dose warrant discontinuation.

Hard contraindications#

These lines do not get crossed:

• Pregnancy — blanket contraindication across the entire Khavinson Cytogen product line. EDL modulates gene expression broadly, and developmental safety data do not exist.
• Lactation — same rationale; excluded per manufacturer labelling.
• Active or suspected hepatic malignancy — the proliferative mechanism is not tumour-selective.
• Documented hypersensitivity to EDL or Cytogen capsule excipients.

Gender and cycle considerations#

Ovagen is non-hormonal, bodyweight-independent, and HPTA-inert. Identical dosing applies across the subject pool — there is no virilization risk, no estrogenic activity, no androgen-receptor interaction, and no impact on semen quality or menstrual cycling. The only gender-specific line is the pregnancy/lactation exclusion above.

PCT: none required. Ovagen does not suppress gonadotropins or affect the HPG axis and can run uninterrupted through a full AAS cycle, through SERM-based PCT (nolvadex, clomid, enclomiphene), and into a cruise or bridge phase without interfering with any of those protocols. It also does not replace a PCT — if the cycle needed one before, it still needs one now. Ovagen simply sits alongside, quietly biasing hepatic gene expression in the right direction while the rest of the stack does its job.